Dulaglutide: What the Evidence Actually Shows

Dulaglutide belongs to the same small category as liraglutide on this site: it is not a compounded or grey-market research peptide, but a real, FDA-approved drug, made by Eli Lilly and sold under one brand name, Trulicity. For years it was one of the most-prescribed GLP-1 drugs in the United States, before semaglutide and tirzepatide's larger weight-loss effect sizes pulled most of the newer attention away from it. This article covers its real approval history, a structural detail most coverage skips (dulaglutide is regulated as a biologic, not a small-molecule drug, for a specific and checkable reason), its own real cardiovascular-outcomes trial, and how it actually performs against liraglutide, semaglutide, and tirzepatide in three separate real head-to-head trials — not by assumption.

The real approval history, and why it's a biologic, not a peptide drug

Trulicity was approved under BLA125469 — a Biologics License Application, not the NDA pathway that covers liraglutide, semaglutide, and exenatide — with an original approval date of September 18, 2014, confirmed directly against openFDA's Drugs@FDA database⁶. That regulatory-pathway difference tracks a real structural one: dulaglutide isn't a peptide alone. It's a fusion protein — a modified GLP-1 receptor agonist peptide, sharing 90% amino acid sequence homology with native human GLP-1, covalently linked via a peptide chain to a human IgG4 heavy-chain constant region (an antibody Fc fragment), assembled as a two-chain, disulfide-linked homodimer⁶. That larger, antibody-fragment-containing structure is a genuinely different molecular design from the peptide-only GLP-1 drugs elsewhere in this corpus, and it's the real basis for FDA regulating it as a biologic rather than a conventional drug.

Two real indications — and one dulaglutide has never received

Trulicity's current label carries two indications, confirmed directly from openFDA's drug label database: glycemic control as an adjunct to diet and exercise in adults and pediatric patients 10 years of age and older with type 2 diabetes, and — a real, FDA-labeled cardiovascular indication — reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors⁶. What the label does not contain is worth stating plainly, since most secondary coverage of the GLP-1 class glosses over it: dulaglutide has never been approved for weight management on its own. Unlike liraglutide (Victoza → Saxenda) and semaglutide (Ozempic → Wegovy), no separate, higher-dose weight-management brand has ever been built on dulaglutide, and no such dose is on file with FDA. That absence matters directly for one of the head-to-head comparisons below.

The real cardiovascular-outcomes trial behind the CV indication

Trulicity's cardiovascular indication rests on REWIND, a large, real hard-outcomes trial — double-blind, randomized, placebo-controlled, enrolling 9,901 adults with type 2 diabetes (4,949 to dulaglutide, 4,952 to placebo) and following them for a median of 5.4 years¹. The primary composite outcome — cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke — occurred in 12.0% of the dulaglutide group versus 13.4% of the placebo group (hazard ratio 0.88, 95% CI 0.79-0.99, p=0.026)¹. That result reached statistical significance; a related one didn't, and this article reports both rather than only the positive one: all-cause mortality was not significantly different between groups (10.8% dulaglutide vs 12.0% placebo, HR 0.90, 95% CI 0.80-1.01, p=0.067)¹. Gastrointestinal adverse events were substantially more common with dulaglutide than placebo (47.4% vs 34.1%, p<0.0001), consistent with the GI-tolerability pattern every drug in this class carries¹. REWIND is real, adequately powered, hard-outcomes evidence — the same category of proof liraglutide's own LEADER trial provides, and genuinely more substantial than most compounds in this site's corpus carry.

How dulaglutide actually compares to liraglutide, semaglutide, and tirzepatide

Dulaglutide has been tested head-to-head against all three of the other GLP-1 drugs already covered on this site, in three separate real randomized trials — not extrapolated from separate placebo trials run years apart.

Against liraglutide (AWARD-6). A 26-week, open-label, non-inferiority trial randomized 599 patients to once-weekly dulaglutide 1.5mg or once-daily liraglutide 1.8mg⁴. HbA1c fell 1.42 percentage points with dulaglutide versus 1.36 with liraglutide — a treatment difference of just -0.06% (95% CI -0.19 to 0.07), meeting the trial's own non-inferiority threshold with room to spare⁴. This is a genuinely different result shape from the two comparisons below: dulaglutide wasn't shown to beat liraglutide, and wasn't shown to lose to it either — the two performed essentially identically on glycemic control over 26 weeks.

Against semaglutide (SUSTAIN 7). A real, dose-matched head-to-head trial randomized 1,201 patients to one of four arms across two dose pairs: semaglutide 0.5mg vs dulaglutide 0.75mg, and semaglutide 1.0mg vs dulaglutide 1.5mg, over 40 weeks². At both matched dose levels, semaglutide outperformed dulaglutide on both endpoints the trial measured. HbA1c: -1.5% (semaglutide 0.5mg) vs -1.1% (dulaglutide 0.75mg), and -1.8% (semaglutide 1.0mg) vs -1.4% (dulaglutide 1.5mg), both differences p<0.0001². Weight: -4.6kg (semaglutide 0.5mg) vs -2.3kg (dulaglutide 0.75mg), and -6.5kg (semaglutide 1.0mg) vs -3.0kg (dulaglutide 1.5mg), both p<0.0001².

Against tirzepatide (SURPASS J-mono). A real, double-blind, randomized trial in Japanese patients compared tirzepatide (5mg, 10mg, or 15mg) against dulaglutide 0.75mg over 52 weeks³. HbA1c fell 2.4-2.8 percentage points with tirzepatide across its three doses, versus 1.3 percentage points with dulaglutide — estimated treatment differences of -1.1 to -1.5 percentage points, all reaching p<0.0001³. The weight-loss gap was larger still: tirzepatide produced 5.8-10.7kg of weight loss (7.8-13.9% of body weight) across its three doses, versus just 0.5kg (0.7%) with dulaglutide³. Read that last number in context rather than as a verdict on dulaglutide's own ceiling: this trial used dulaglutide 0.75mg, its standard type-2-diabetes starting dose — not a weight-focused dose, because (as covered above) no such dose exists for dulaglutide at all. Tirzepatide's own weight-loss advantage here is real and large, but the comparison itself is closer to "a diabetes-dosed drug against a drug specifically engineered and dosed for weight loss" than a fully matched contest.

The safety picture, read from the label itself

Trulicity's boxed warning is the same class-wide rodent-carcinogenicity finding liraglutide's own label carries, confirmed independently for dulaglutide's own current label rather than assumed to transfer: "In male and female rats, dulaglutide causes a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure. It is unknown whether TRULICITY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans⁶." Trulicity is contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2. As with liraglutide, this is a rodent finding of undetermined human relevance, stated by FDA at exactly that precision — a real regulatory fact worth reading in its own words rather than a summary, and not a signal that dulaglutide carries a distinct risk the rest of the class doesn't.

Why this site doesn't have a dulaglutide reconstitution calculator

Every FDA-approved dulaglutide strength — 0.75mg, 1.5mg, 3mg, and 4.5mg — ships as a ready-to-use solution in a single-dose pen, confirmed directly from the current label's own Dosage Forms and Strengths section⁶. There is no lyophilized powder and no reconstitution step for any Trulicity presentation. A direct check of this site's own provider-compound records ("sells.ts" and "other-compounds.ts") found zero mentions of dulaglutide or Trulicity — no reviewed provider on this roster sells it as a compounded product. No "/calculator/dulaglutide" page is built, for the same reason liraglutide didn't get one: there is no real vial-and-diluent product on the market for this molecule to build a calculator against.

What this means if you're considering it

None of the 31 providers this site's own reviews cover sell dulaglutide as a boarded product — it is not a compounded-market compound the way tirzepatide, sermorelin, and semaglutide are. Put simply: dulaglutide is a real, once-weekly GLP-1 fusion-protein drug with a genuine cardiovascular-outcomes indication behind it, structurally distinct enough from the peptide-only GLP-1 drugs to be regulated as a biologic, and it has never been positioned or dosed for weight management on its own. In head-to-head trials it performed essentially the same as liraglutide, meaningfully worse than semaglutide, and substantially worse than tirzepatide on both glycemic control and weight loss — though that last comparison used dulaglutide's standard diabetes dose, not a weight-focused one, because no such dose exists for this drug. For the newer drugs this site covers in more depth, our tirzepatide vs. semaglutide evidence review and our liraglutide evidence review cover those comparisons directly; for Eli Lilly's newest GLP-1 drug — its first oral one — see our orforglipron evidence review.